Latest Breaking News On - Sesen bio - Page 1 : comparemela.com

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ Carisma Therapeutics Inc. (NASDAQ: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and.

United statesJohn hohnekerSteven kellyShveta digheChidozie ugwumbaPrnewswire carisma therapeutics incCarisma therapeutics incModerna tx incCompany annual report on formDrug administrationSesen bio incExchange commissionBoard of directors the companyWhile the companyChief executive officerPipeline updates

Carisma Therapeutics (CARM) Reports Q4, Provides Business Update

Carisma Therapeutics (CARM) Reports Q4, Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John hohnekerSteven kellyChidozie ugwumbaModerna tx incCarisma therapeutics incBoard of directors the companyWhile the companySesen bio incDrug administrationCarisma therapeuticsChief executive officerPipeline updatesUpcoming milestonesInvestigational new drugModerna collaborationFull year

Carisma lightens load to stretch cash runway into Q3 2025

Carisma lightens load to stretch cash runway into Q3 2025
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesSteven kellyCarisma therapeuticsSesen bioBig biotech

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

United statesBristol myers squibbBristol myers squibb sanofiMedivation astellasImmunitybio incyteMerck seronoNonagen bioscienceAstellas pharmaJiangsu yahong meditechTelix pharmaceuticalsCarolina urologic research centerAsieris pharmaceuticalsFoundation medicineClarity pharmaceuticalsAragon pharmaceuticalsSpeciality networks

CG Oncology s Lead Bladder Cancer Drug Offers Buyout Optionality (CGON)

CG Oncology s Lead Bladder Cancer Drug Offers Buyout Optionality (CGON)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbMerck keytrudaJanus hendersonMorgan stanleyGoldman sachsBladder cancer advocacy networkCg oncology incRayzebio incImmunitybio incEnd drug shortages alliancePfizer incMerck co incCantor fitzgeraldBristol myers squibb companyProtara therapeutics inc